Cardiovascular Events Associated With Smoking Cessation Pharmacotherapies | Zendy

Edward J. Mills | Zendy; Kristian Thorlund | Zendy; Shawn Eapen | Zendy; Ping Wu | Zendy; Judith J. Prochaska | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Cardiovascular Events Associated With Smoking Cessation Pharmacotherapies

Author(s) -

Edward J. Mills,

Kristian Thorlund,

Shawn Eapen,

Ping Wu,

Judith J. Prochaska

Publication year - 2013

Publication title -

circulation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.795

H-Index - 607

eISSN - 1524-4539

pISSN - 0009-7322

DOI - 10.1161/circulationaha.113.003961

Subject(s) - medicine , smoking cessation , intensive care medicine , pathology

Stopping smoking is associated with many important improvements in health and quality of life. The use of cessation medications is recommended to increase the likelihood of quitting. However, there is historical and renewed concern that smoking cessation therapies may increase the risk of cardiovascular disease events associated within the quitting period. We aimed to examine whether the 3 licensed smoking cessation therapies-nicotine replacement therapy, bupropion, and varenicline-were associated with an increased risk of cardiovascular disease events using a network meta-analysis.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research